Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$65.56
0.901.39%
At close: -
$65.56
0.000.00%
After Hours: Jun 20, 4:00 PM EDT
Comments
Loading...
ANI Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ANIP | Benzinga
ANI Pharmaceuticals Inc has a consensus price target of $80.13 based on the ratings of 9 analysts. The high is $94 issued by HC Wainwright & Co. on March 17, 2025. The low is $65 issued by Truist Securities on April 21, 2025. The 3 most-recent analyst ratings were released by Guggenheim, Truist Securities, and Guggenheim on May 12, 2025, April 21, 2025, and April 11, 2025, respectively. With an average price target of $79 between Guggenheim, Truist Securities, and Guggenheim, there's an implied 20.50% upside for ANI Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Truist Securities
HC Wainwright & Co.
Jefferies
JP Morgan
1calculated from analyst ratings
Analyst Ratings for ANI Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/12/2025 | Buy Now | 31.18% | Guggenheim | Vamil Divan74% | $86 → $86 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2025 | Buy Now | -0.85% | Truist Securities | Gregory Fraser63% | $62 → $65 | Maintains | Hold | Get Alert |
| 04/11/2025 | Buy Now | 31.18% | Guggenheim | Vamil Divan74% | $86 → $86 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 43.38% | HC Wainwright & Co. | Oren Livnat60% | $94 → $94 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2025 | Buy Now | 22.03% | Jefferies | Glen Santangelo51% | → $80 | Initiates | → Buy | Get Alert |
| 03/12/2025 | Buy Now | 29.65% | JP Morgan | Ekaterina Knyazkova27% | → $85 | Initiates | → Overweight | Get Alert |
| 03/05/2025 | Buy Now | 31.18% | Guggenheim | Vamil Divan74% | $84 → $86 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | 43.38% | HC Wainwright & Co. | Oren Livnat60% | $94 → $94 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | 22.03% | Leerink Partners | Faisal Khurshid40% | → $80 | Initiates | → Outperform | Get Alert |
| 11/11/2024 | Buy Now | 43.38% | HC Wainwright & Co. | Oren Livnat60% | $94 → $94 | Reiterates | Buy → Buy | Get Alert |
| 10/22/2024 | Buy Now | -5.43% | Truist Securities | Gregory Fraser63% | $60 → $62 | Maintains | Hold | Get Alert |
| 10/11/2024 | Buy Now | 3.72% | Piper Sandler | David Amsellem73% | → $68 | Initiates | → Overweight | Get Alert |
| 09/18/2024 | Buy Now | 26.6% | Raymond James | Elliot Wilbur45% | $81 → $83 | Maintains | Outperform | Get Alert |
| 09/17/2024 | Buy Now | 43.38% | HC Wainwright & Co. | Oren Livnat60% | $94 → $94 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | -8.48% | Truist Securities | Gregory Fraser63% | $80 → $60 | Downgrade | Buy → Hold | Get Alert |
| 08/07/2024 | Buy Now | 43.38% | HC Wainwright & Co. | Oren Livnat60% | $94 → $94 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 43.38% | HC Wainwright & Co. | Oren Livnat60% | $87 → $94 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 32.7% | HC Wainwright & Co. | Oren Livnat60% | $83 → $87 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | 17.45% | Guggenheim | Vamil Divan74% | $77 → $77 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | — | Capital One | Timothy Chiang24% | — | Initiates | → Overweight | Get Alert |
| 03/05/2024 | Buy Now | 17.45% | Guggenheim | Vamil Divan74% | $70 → $77 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 26.6% | HC Wainwright & Co. | Oren Livnat60% | $73 → $83 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 22.03% | Truist Securities | Gregory Fraser63% | $72 → $80 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 9.82% | Truist Securities | Gregory Fraser63% | $70 → $72 | Maintains | Buy | Get Alert |
| 10/19/2023 | Buy Now | 9.82% | Guggenheim | Vamil Divan74% | → $72 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 9.82% | Guggenheim | Vamil Divan74% | → $72 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | 11.35% | HC Wainwright & Co. | Oren Livnat60% | $60 → $73 | Maintains | Buy | Get Alert |
| 08/21/2023 | Buy Now | 6.77% | Truist Securities | Gregory Fraser63% | → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 9.82% | Guggenheim | Vamil Divan74% | $62 → $72 | Maintains | Buy | Get Alert |
| 07/27/2023 | Buy Now | -5.43% | Guggenheim | Vamil Divan74% | $59 → $62 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | -8.48% | Truist Securities | Gregory Fraser63% | $52 → $60 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -10.01% | Guggenheim | Vamil Divan74% | $55 → $59 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -20.68% | Truist Securities | Gregory Fraser63% | $50 → $52 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -25.26% | Raymond James | Elliot Wilbur45% | $48 → $49 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | -8.48% | HC Wainwright & Co. | Oren Livnat60% | $53 → $60 | Maintains | Buy | Get Alert |
| 03/13/2023 | Buy Now | -19.16% | HC Wainwright & Co. | Oren Livnat60% | $50 → $53 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | -16.11% | Guggenheim | Vamil Divan74% | → $55 | Initiates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | -23.73% | HC Wainwright & Co. | Oren Livnat60% | → $50 | Reiterates | → Buy | Get Alert |
| 09/07/2022 | Buy Now | -23.73% | HC Wainwright & Co. | Oren Livnat60% | → $50 | Initiates | → Buy | Get Alert |
| 08/09/2022 | Buy Now | -26.78% | Raymond James | Elliot Wilbur45% | $47 → $48 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for ANI Pharmaceuticals (ANIP) stock?
The latest price target for ANI Pharmaceuticals (NASDAQ:ANIP) was reported by Guggenheim on May 12, 2025. The analyst firm set a price target for $86.00 expecting ANIP to rise to within 12 months (a possible 31.18% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ANI Pharmaceuticals (ANIP)?
The latest analyst rating for ANI Pharmaceuticals (NASDAQ:ANIP) was provided by Guggenheim, and ANI Pharmaceuticals reiterated their buy rating.
When was the last upgrade for ANI Pharmaceuticals (ANIP)?
There is no last upgrade for ANI Pharmaceuticals
When was the last downgrade for ANI Pharmaceuticals (ANIP)?
The last downgrade for ANI Pharmaceuticals Inc happened on September 11, 2024 when Truist Securities changed their price target from $80 to $60 for ANI Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ANI Pharmaceuticals (ANIP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ANI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ANI Pharmaceuticals was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.
Is the Analyst Rating ANI Pharmaceuticals (ANIP) correct?
While ratings are subjective and will change, the latest ANI Pharmaceuticals (ANIP) rating was a reiterated with a price target of $86.00 to $86.00. The current price ANI Pharmaceuticals (ANIP) is trading at is $65.56, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
